首页 | 本学科首页   官方微博 | 高级检索  
检索        


CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
Authors:T Fukusumi  H Ishii  M Konno  T Yasui  S Nakahara  Y Takenaka  Y Yamamoto  S Nishikawa  Y Kano  H Ogawa  S Hasegawa  A Hamabe  N Haraguchi  Y Doki  M Mori  H Inohara
Abstract:

Background:

Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).

Methods:

Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.

Results:

CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.

Conclusions:

CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.
Keywords:CD10  head and neck squamous cell carcinoma  cell surface antigen array  chemo-resistance  radio-resistance  cancer stem cells
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号